PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
https://doi.org/10.20996/1819-6446-2008-4-4-69-75
Abstract
Angiotensin II receptor antagonists (ARA) established their position recently duet to new indications above arterial hypertension (HT). These are chronic heart failure, history of myocardial infarction, atrial fibrillation and metabolic syndrome. Analysis of evidence basis, including recently published biggest international clinical studies, was performed in the article. Data demonstrate that ARA can be effectively and safely used in wide clinical practice for improvement of life quality and life prolongation in patients with HT.
About the Authors
S. A. Boytsov
Russian Cardiology Research and Production Center of Rosmedtechnology, Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation
Russian Federation
I. P. Kolos
Russian Cardiology Research and Production Center of Rosmedtechnology, Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia
Russian Federation
Russian Federation
References
1. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
2. Mochizuki S., Dahlöf B., Shimizu M., et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9.
3. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.
4. Yusuf S., Diener H.C., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37.
5. Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329: 1248-9.
6. Papademetriou V., Farsang C., Elmfeldt D., et al. Stroke prevention with the angiotensin II type 1- receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175-80.
7. Brenner B.M., Cooper M.E., de Zeeuw D., et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
8. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
9. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.
10. Turnbull F., Neal B., Algert C., et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-9.
11. Reboldi G., Angeli F., Cavallini C., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptors blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008,26:1282-9.
12. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
13. Schrader J., Lüders S., Kulschewski A., et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26.
14. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31.
15. McMurray J. Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate [letter]. BMJ 2005;330;1269.
16. McDonald M.A., Simpson S.H., Ezekowitz J.A. et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005;331;873-9.
17. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832–9.
18. Ducharme A., Swedberg K., Pfeffer M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152(1):86-92.
19. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548-57.
20. Madrid A.H., Bueno M.G., Rebollo J.M. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-6.
Review
For citations:
Boytsov S.A., Kolos I.P. PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY. Rational Pharmacotherapy in Cardiology. 2008;4(4):69-75. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-4-69-75
Views:
596
Email this article 